The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 statusTanja Fehm, Jonathan W. Uhr|Breast Cancer Research|2007Cited by 195
Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patientsNatalia Krawczyk, Tanja Fehm|BMC Cancer|2019Cited by 20
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Massimo Cristofanilli, Jean‐Yves Pierga et al.|The Oncologist|2022Cited by 13
Current landscape of hospital information systems in gynecology and obstetrics in Germany: a survey of the commission Digital Medicine of the German Society for Gynecology and ObstetricsAndré Pfob, Armin Wöckel, Max Hackelöer et al.|Archives of Gynecology and Obstetrics|2023Cited by 8